Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Navidea Biopharmaceuticals, Inc. (NAVB)

0.27   0.004 (1.39%) 12-05 16:00
Open: 0.298 Pre. Close: 0.2663
High: 0.298 Low: 0.27
Volume: 35,713 Market Cap: 9(M)

Technical analysis

as of: 2022-12-06 7:50:00 AM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 0.35     One year: 0.4
Support: Support1: 0.23    Support2: 0.2
Resistance: Resistance1: 0.3    Resistance2: 0.35
Pivot: 0.25
Moving Average: MA(5): 0.25     MA(20): 0.25
MA(100): 0.34     MA(250): 0.67
MACD: MACD(12,26): 0     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 71.1     %D(3): 64.6
RSI: RSI(14): 57
52-week: High: 1.34  Low: 0.2
Average Vol(K): 3-Month: 104 (K)  10-Days: 61 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ NAVB ] has closed below upper band by 26.7%. Bollinger Bands are 31.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.3 - 0.3 0.3 - 0.3
Low: 0.27 - 0.27 0.27 - 0.27
Close: 0.27 - 0.27 0.27 - 0.27

Company Description

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Headline News

Mon, 28 Nov 2022
2022-11-28 | NYSEAM:NAVB | Press Release | Navidea Biopharmaceuticals Inc. - Stockhouse

Tue, 15 Nov 2022
Navidea Biopharmaceuticals, Inc. (NAVB) Q3 2022 Earnings Call Transcript - Seeking Alpha

Mon, 14 Nov 2022
Navidea: Q3 Earnings Snapshot - San Francisco Chronicle

Mon, 07 Nov 2022
Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting - Business Wire

Fri, 30 Sep 2022
Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders - Yahoo Finance

Thu, 25 Aug 2022
Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering - Business Wire

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 30 (M)
% Held by Insiders 2.158e+007 (%)
% Held by Institutions 28.2 (%)
Shares Short 141 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.115e+007
EPS Est Next Qtl 0
EPS Est This Year -0.08
EPS Est Next Year -0.03
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 602.1
Return on Equity (ttm) -93.8
Qtrly Rev. Growth 700420
Gross Profit (p.s.) -36.22
Sales Per Share -244.65
EBITDA (p.s.) 516367
Qtrly Earnings Growth -0.4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -10 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 4.34

Stock Dividends

Dividend 0
Forward Dividend 136160
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.